Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

anti-CD163 monoclonal antibody OR2805

A human immunoglobulin G1 (IgG1) monoclonal antibody directed against the immunosuppressive receptor CD163 (scavenger receptor cysteine-rich type 1 protein M130), with potential immunomodulating and antineoplastic activities. Upon administration, anti-CD163 monoclonal antibody OR2805 targets and binds to CD163 expressed on immunosuppressive tumor-associated macrophages (TAMs) within the tumor microenvironment (TME), and prevents the binding of CD163 to its ligands. This inhibits CD163-mediated immunosuppression, including the secretion of immunosuppressive cytokines and the inhibition of T-cell activation. This enhances T-cell activation and proliferation and antitumor T-cell immune responses, which inhibits the proliferation of tumor cells. CD163, an immunosuppressive receptor highly expressed on TAMs, plays an important role in immunosuppression and the inhibition of anti-tumor T-cell immune responses.
Code name:OR 2805
OR-2805
OR2805
Search NCI's Drug Dictionary